3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Respiratory Tract Diseases
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Intraductal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Interventions
pembrolizumab
3
Carboplatin
3
selpercatinib
2
durvalumab
2
Pemetrexed
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
Telescopes
1
Radiosurgery
1
Paclitaxel
1
Gemcitabine
1
Gefitinib
1
Erlotinib Hydrochloride
1
Bevacizumab
1
AZD3759
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
Erlotinib Hydrochloride
×
1 year
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled